patient
age
year
receiv
singl
doubl
lung
transplant
januari
april
sahlgrenska
univers
hospit
transplant
centr
swedish
resid
surviv
initi
postop
intens
care
period
ask
particip
studi
approv
region
ethic
review
board
gothenburg
subject
provid
written
verbal
inform
consent
data
collect
prospect
standard
followup
protocol
use
patient
visit
outlin
figur
induct
therapi
consist
rabbit
antithymocyt
globulin
given
consecut
day
togeth
methylprednisolon
iv
posttransplant
immunosuppress
includ
prednison
mgkgday
mycophenol
mofetil
gd
patient
receiv
either
oral
cyclosporin
csa
mgkg
adjust
maintain
serum
level
ngml
tacrolimu
tac
mgkg
given
oral
divid
dose
daili
adjust
maintain
serum
level
ngml
dosag
immunosuppress
gradual
lower
fu
chang
immunosuppress
therapi
base
clinic
present
antimicrobi
prophylaxi
detail
supplementari
materi
http
extra
followup
visit
addit
bronchoscopi
carri
upon
suspicion
respiratori
infect
ar
base
clinic
present
everi
visit
symptom
vrti
record
fever
cough
sputum
coryza
headach
wheez
short
breath
muscular
pain
rash
eye
red
sore
throat
patient
present
symptom
vrti
consid
symptomat
clinic
data
followup
visit
infecti
event
includ
detail
regard
immunosuppress
manag
record
electron
case
report
form
patient
regular
contact
transplant
nurs
follow
end
studi
period
graft
loss
chronic
lung
allograft
dysfunct
defin
irrevers
loss
least
baselin
forc
expiratori
volum
first
second
reason
declin
exclud
forc
vital
capac
reduc
least
total
lung
capac
reduc
least
function
loss
consid
predominantli
lung
function
screen
weekli
use
home
spiromet
convent
spirometri
perform
loss
forc
expiratori
volum
first
second
forc
vital
capac
identifi
arrang
transplant
nurs
part
clinic
routin
two
experienc
transplant
pulmonologist
review
patient
separ
clad
develop
use
avail
spirometri
data
result
compar
consensu
reach
discrep
graft
loss
defin
either
death
retransplant
train
nurs
obtain
nasopharyng
nph
sampl
use
eswab
copan
brescia
itali
swab
put
contain
ml
ami
medium
immedi
transport
laboratori
frozen
analyz
nph
bal
sampl
test
use
multiplex
realtim
pcr
panel
respiratori
pathogen
addit
sampl
test
realtim
pcr
detect
legionella
pneumophila
pneumocysti
jirovecii
cytomegaloviru
cmv
bronchoscopi
bal
perform
standard
manner
http
nph
perform
bronchoscopi
bronchoscopi
perform
use
either
laryng
tracheal
tube
avoid
crosscontamin
bal
sampl
test
convent
bacteri
fungal
cultur
seriou
infect
suspect
blood
urin
cultur
also
perform
upper
lower
vrti
defin
detect
viral
pathogen
realtim
pcr
either
nph
bal
fluid
sampl
subject
posit
pcr
test
least
viral
pathogen
either
bal
nph
sampl
first
year
consid
vrti
posit
bacteri
respiratori
tract
infect
defin
posit
cultur
bacteria
bal
sputum
symptom
consist
respiratori
tract
infect
evalu
experienc
transplant
pulmonologist
fungal
infect
defin
signific
presenc
aspergillu
candida
bal
andor
sputum
cultur
symptom
andor
bronchoscop
find
consist
fungal
infect
signific
cmv
viremia
defin
increas
level
cmvdna
blood
seroneg
transplant
recipi
cmvdna
detect
first
time
cmvseroposit
recipi
level
increas
copiesml
repeat
elev
epsteinbarr
viru
ebv
dna
reed
defin
separ
ebvdna
measur
copiesml
least
month
apart
acut
reject
defin
either
lung
biopsi
show
reject
intern
societi
heart
lung
transplant
grade
absenc
biopsi
n
typic
physic
radiolog
find
follow
prompt
respons
highdos
corticosteroid
therapi
level
cmv
ebvdna
determin
whole
blood
use
realtim
pcr
realtim
pcr
system
appli
biosystem
foster
citi
ca
previous
primer
probe
sequenc
present
supplement
materi
http
nph
bal
sampl
obtain
nucleic
acid
isol
describ
sampl
analyz
use
multiplex
pcr
system
design
detect
adenoviru
bocaviru
chlamydophila
pneumonia
human
coronavirus
cov
human
enteroviru
human
metapneumoviru
human
rhinoviru
hrv
influenza
b
mycoplasma
pneumonia
parainfluenza
viru
respiratori
syncyti
viru
rsv
multiplex
pcr
method
describ
studi
period
novel
manag
donor
organ
introduc
form
ex
vivo
lung
perfus
evlp
http
therefor
post
hoc
analysi
impact
evlp
cohort
ad
comparison
group
level
numer
variabl
perform
use
mannwhitney
u
test
categor
variabl
fisher
exact
test
kaplanmei
analysi
logrank
test
use
calcul
compar
cladfre
surviv
time
graft
loss
timeindepend
covari
acut
reject
bacteri
infect
fungal
infect
vrti
cmv
viremia
reed
handl
timedepend
covari
appropri
assign
hazard
univari
cox
proport
hazard
model
use
examin
associ
covari
cladfre
surviv
graft
loss
respect
covari
p
valu
less
univari
analysi
includ
multivari
model
spss
softwar
packag
version
ibm
armonk
ny
use
statist
analys
p
valu
less
consid
signific
vrtiposit
patient
statist
signific
differ
regard
baselin
characterist
vrtiposit
neg
patient
tabl
first
year
followup
vrti
detect
visit
lower
vrti
visit
surveil
bronchoscopi
perform
viru
detect
upper
nph
lower
bal
airway
case
symptomat
median
rate
viral
infect
patient
suffer
viral
infect
wherea
patient
viral
infect
six
patient
posit
viru
least
sampl
total
sampl
detect
patient
viru
found
least
consecut
sampl
least
week
apart
vrtiposit
patient
mean
time
first
viral
infect
ltx
week
major
detect
virus
hrv
follow
frequenc
cov
figur
human
rhinoviru
detect
across
season
cov
mostli
winter
spring
figur
sampl
rsv
detect
anoth
sampl
enteroviru
detect
metapneumoviru
parainfluenza
adenoviru
detect
sampl
fewer
case
influenza
viru
detect
patient
treat
antivir
drug
patient
vaccin
influenza
transplant
total
patient
suffer
ar
first
year
patient
suffer
ar
develop
clad
bacteri
infect
affect
patient
consist
pseudomona
aeruginosa
case
remaind
bacteria
fungal
infect
affect
patient
case
candida
glabrata
case
candida
krusei
rest
consist
aspergillu
speci
total
patient
show
cmv
antibodi
mismatch
patient
least
episod
cmv
viremia
first
year
patient
develop
cmv
diseas
followup
period
repeat
elev
ebvdna
common
patient
suffer
episod
epsteinbarr
viremia
three
patient
develop
posttranspl
lymphoprolif
diseas
followup
respond
favor
treatment
acut
reject
infecti
event
outlin
tabl
case
posit
pcr
legionella
pneumophila
pneumocysti
jirovecii
chlamydophila
pneumonia
mycoplasma
pneumonia
detect
end
followup
patient
diagnos
clad
tabl
predominantli
restrict
predominantli
obstruct
total
patient
suffer
organ
loss
patient
die
retransplant
twelv
death
occur
first
year
major
caus
organ
loss
clad
n
signific
caus
infect
n
malign
n
chronic
lung
allograft
dysfunct
develop
followup
period
common
among
vrti
posit
subject
p
tabl
significantli
common
clad
caus
organ
loss
among
suffer
vrti
p
found
signific
differ
regard
graft
surviv
end
followup
patient
without
vrti
p
tabl
vrtiposit
subject
significantli
higher
hazard
ratio
hr
clad
develop
multivari
analysi
p
tabl
found
signific
differ
time
graft
loss
p
howev
among
suffer
organ
loss
time
clad
develop
organ
loss
significantli
longer
vrti
develop
clad
compar
none
p
bacteri
p
fungal
p
infect
associ
shorter
time
graft
loss
univari
analysi
follow
variabl
includ
multivari
model
immunosuppress
treatment
csa
oppos
tac
age
transplant
singl
lung
transplant
reed
copd
diagnosi
vrti
posit
least
episod
ar
cystic
fibrosi
cf
diagnosi
includ
multivari
analysi
tabl
multivari
analysi
vrtiposit
hr
csa
treatment
hr
least
episod
ar
hr
remain
independ
predict
clad
figur
show
effect
csa
treatment
kaplanmei
plot
individu
viral
agent
cov
identifi
timedepend
risk
factor
p
hr
clad
develop
associ
persist
multivari
analysi
use
cofactor
previou
analysi
p
hr
observ
separ
evalu
differ
cov
subtyp
type
viru
simultan
detect
singl
test
associ
clad
multivari
cox
perform
covari
previou
analysi
p
hr
http
symptomat
vrti
p
vrti
bal
fluid
p
associ
clad
post
hoc
analysi
transplant
recipi
receiv
lung
treat
evlp
n
show
signific
differ
risk
clad
develop
p
graft
loss
p
compar
lung
present
studi
vrti
first
year
followup
ltx
signific
risk
factor
clad
develop
found
associ
graft
surviv
ar
first
year
independ
risk
factor
clad
develop
expect
interestingli
csa
treatment
also
significantli
associ
clad
khalifah
et
present
data
suggest
respiratori
viral
infect
distinct
risk
bo
recent
allyn
et
report
clad
develop
hasten
viral
pneumonia
defin
symptomat
viral
infect
radiograph
infiltr
without
clear
altern
explan
studi
includ
bal
sampl
expector
sputum
tracheal
suction
well
nph
wash
sampl
primarili
analyz
cultur
pcr
onward
indic
major
sampl
bal
sampl
main
detect
method
culturebas
might
explain
lower
proport
vrtiposit
subject
compar
studi
prospect
studi
fisher
et
publish
retrospect
studi
patient
least
followup
test
vrti
perform
upon
clinic
suspicion
surveil
test
carri
sampl
test
use
differ
method
includ
pcr
fluoresc
microscopi
cultur
found
timedepend
relationship
clad
develop
month
vrti
hr
declin
time
event
also
show
ar
signific
risk
factor
clad
develop
data
suggest
particular
coronavirus
might
contribut
clad
develop
sooner
transplant
previous
report
although
hrv
commonli
detect
viral
agent
seem
contribut
less
clad
develop
http
coronaviru
subtyp
usual
replic
nph
epitheli
cell
gener
caus
mild
symptom
otherwis
healthi
clear
case
among
immunocompromis
studi
found
coronaviru
subtyp
lower
airway
find
fit
previou
studi
report
prefer
type
alveolar
known
trigger
innat
immun
system
cell
mediat
adapt
immun
howev
number
cov
subtyp
well
number
virus
viral
famili
subgroup
analysi
find
ar
risk
factor
clad
develop
uncontroversi
effect
choic
calcineurin
inhibit
clad
develop
previous
center
gener
select
bia
toward
tacrolimu
instead
csa
younger
patient
cf
patient
also
patient
retranspl
tac
select
often
http
high
hr
clad
develop
associ
csa
treatment
somewhat
unexpect
studi
design
compar
impact
differ
type
immunosuppress
result
must
interpret
witch
caution
find
associ
vrti
time
graft
loss
howev
major
clad
popul
previou
vrti
exposur
suffer
rel
slowli
progress
bo
compar
clad
popul
previou
vrti
exposur
could
suggest
clad
phenotyp
trigger
vrti
less
aggress
clad
trigger
caus
found
associ
lower
vrti
clad
contrast
previou
find
howev
survey
bronchoscopi
detect
lower
vrti
simultan
find
viru
upper
airway
perform
asymptomat
patient
case
like
patient
asymptomat
upper
vrti
detect
surveil
sampl
without
bronchoscopi
also
lower
vrti
thu
true
impact
lower
vrti
may
underestim
hypothet
mechan
graft
damag
disturb
repair
mechan
due
decreas
regulatori
treg
cell
activ
caus
immunosuppress
treatment
function
treg
cell
suppress
prolifer
fibroblast
trigger
cytotox
cell
cell
attack
infect
respiratori
epitheli
cell
absenc
treg
cell
immunosuppress
patient
might
lead
poor
control
inflammatori
respons
dysregul
epitheli
repair
thu
immun
respons
induc
vrti
earli
lung
transplant
might
stop
clearanc
viru
caus
epitheli
injuri
fibroprolifer
lead
reduc
lung
function
studi
sever
limit
first
studi
design
releas
standard
definit
infect
cardiothorac
transplant
recipi
releas
intern
societi
heart
lung
transplant
would
prefer
futur
refer
episod
result
contact
physician
record
case
report
form
systemat
record
clinic
data
except
spirometri
data
avail
visit
studi
evalu
known
risk
factor
gastroesophag
reflux
environment
pollut
exposur
ltx
furthermor
respect
high
number
asymptomat
vrti
would
prefer
keep
sampl
interv
constant
increas
time
sampl
end
first
year
might
introduc
bia
toward
effect
earli
infect
frequent
surveil
bronchoscopi
analyz
frequenc
asymptomat
lower
vrti
ltx
would
also
prefer
viral
sequenc
perform
make
difficult
certain
whether
patient
viru
sequenti
sampl
suffer
persist
infect
experienc
multipl
reinfect
differ
subtyp
viru
longterm
effect
earli
vrti
domin
asymptomat
vrti
indic
find
suggest
improv
vrti
prophylaxi
might
promot
favor
outcom
ltx
howev
present
effect
drug
exist
new
antivir
compound
could
evalu
treat
ltx
recipi
need
conclus
studi
suggest
vrti
first
postop
year
particular
caus
coronaviru
could
import
risk
factor
longterm
clad
develop
use
systemat
prospect
record
symptom
also
found
major
vrti
asymptomat
mechanist
studi
viral
interact
transplant
lung
larger
multicent
trial
use
standard
sampl
diagnost
method
warrant
better
understand
effect
viral
infect
longterm
outcom
ltx
